Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATRiX Trial: Tuvusertib +/- Avelumab in Advanced PD-(L)1-Refractory Merkel Cell Carcinoma
NCT05947500Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2024
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of tuvusertib in Merkel cell carcinoma (MCC), sponsored by National Cancer Institute. Started May 2024; status: active, not recruiting.
02
Drugs
tuvusertib
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT05947500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05947500.